CON trades 2.0% above Wall Street's consensus target of $31.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes CON achieves its forward estimates and maintains a stable P/E multiple of 20.8x. This scenario reflects the blended consensus of 6 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of July 8, 2026, Concentra Group Holdings Parent, Inc. (CON) has a Wall Street consensus price target of $31.00, based on estimates from 6 covering analysts. With the stock currently trading at $31.63, this represents a potential downside of -2.0%. The company has a market capitalization of $4.05B.
Analyst price targets range from a low of $30.00 to a high of $32.00, representing a 6% spread in expectations. The median target of $31.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 6 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, CON trades at a trailing P/E of 24.3x and forward P/E of 20.8x. Analysts expect EPS to grow +9.3% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $38.90, with bear and bull scenarios of $24.51 and $51.26 respectively. Model confidence stands at 50/100, reflecting moderate uncertainty in projections.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
AMSFAMERISAFE, Inc. | $663M | $35.45 | $44.50 | +25.5% | Buy | 16.9x | 6 |
OHIOmega Healthcare Investors, Inc. | $14.8B | $49.62 | $50.43 | +1.6% | Hold | 25.0x | 28 |
ACHCAcadia Healthcare Company, Inc. | $2.9B | $31.92 | $28.33 | -11.2% | Buy | 21.2x | 25 |
SEMSelect Medical Holdings Corporation | $2.0B | $16.51 | $17.75 | +7.5% | Hold | 13.5x | 14 |
USPHU.S. Physical Therapy, Inc. | $1.1B | $71.80 | $96.00 | +33.7% | Buy | 25.7x | 13 |
ATIATI Inc. | $25.1B | $183.26 | $175.00 | -4.5% | Buy | 41.5x | 29 |
ALHCAlignment Healthcare, Inc. | $4.9B | $24.05 | $24.33 | +1.2% | Buy | 126.2x | 16 |
CCRNCross Country Healthcare, Inc. | $427M | $13.22 | $12.50 | -5.4% | Hold | 142.9x | 14 |
AMNAMN Healthcare Services, Inc. | $1.3B | $33.25 | $27.00 | -18.8% | Buy | 12.5x | 17 |
OPCHOption Care Health, Inc. | $3.4B | $21.57 | $31.22 | +44.7% | Buy | 11.7x | 14 |
Quick answers to the most common questions about buying CON stock.
Wall Street's consensus price target for CON is $31, -2.0% from its current price of $31.63. The below-market target from 6 analysts suggests limited near-term appreciation.
CON has a consensus rating of "Buy" based on 6 Wall Street analysts. The rating breakdown is predominantly bullish, with 6 Buy/Strong Buy ratings. The consensus 12-month price target of $31 implies -2.0% downside from current levels.
CON trades at a forward P/E of 20.8435x, representing a moderate valuation. With analysts targeting $31 (-2.0% implied move), the stock appears close to fair value.
The most bullish Wall Street analyst has a price target of $32 for CON, while the most conservative target is $30. The consensus of $31 represents the median expectation. Our quantitative valuation model projects a bull case target of $51 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
CON is moderately covered, with 6 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 6 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month CON stock forecast based on 6 Wall Street analysts shows a consensus price target of $31, with estimates ranging from $30 (bear case) to $32 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $39, with bear/bull scenarios of $25/$51.
Our quantitative valuation model calculates CON's fair value at $39 (base case), with a bear case of $25 and bull case of $51. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 50/100.
CON trades at a forward P/E ratio of 20.8x based on next-twelve-months earnings estimates compared to a trailing P/E of 24.3x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Analysts are cautious on CON, with 0 Sell ratings and a price target of $31 (-2.0% from current price). The "Buy" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
CON analyst price targets range from $30 to $32, a 6% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $31 consensus represents the middle ground. Our model's $25-$51 range provides an independent fundamental perspective.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.